---
audienceLevel: patient
cancerTypes:
- breast
- lung
- colorectal
- prostate
- pancreatic
- liver
- kidney
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- pdq
- treatment
title: Coenzyme Q10 (PDQ®) - NCI
url: https://www.cancer.gov/about-cancer/treatment/cam/hp/coenzyme-q10-pdq
version: v1
---

# Coenzyme Q10 (PDQ®) - NCI

# Coenzyme Q10 (PDQ®)–Health Professional Version

## Overview

[Go to Patient Version](/about-cancer/treatment/cam/patient/coenzyme-q10-pdq)

This [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov) information summary provides an overview of
the use of [coenzyme](/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=English&dictionary=Cancer.gov) Q10 in cancer therapy. The summary includes a
history of coenzyme Q10 research, a review of [laboratory studies](/Common/PopUps/popDefinition.aspx?id=44512&version=healthprofessional&language=English&dictionary=Cancer.gov),
and data from investigations involving human subjects. Although several
naturally occurring forms of coenzyme Q have been identified, Q10
is the predominant form found in humans and most mammals, and it is the form
most studied for [therapeutic](/Common/PopUps/popDefinition.aspx?id=43985&version=healthprofessional&language=English&dictionary=Cancer.gov)
potential. Thus, it will be the only form of coenzyme Q discussed in this
summary.

This summary contains the following key information:

- Coenzyme Q10 is made naturally by the human body.
- Coenzyme Q10 helps [cells](/Common/PopUps/popDefinition.aspx?id=46476&version=healthprofessional&language=English&dictionary=Cancer.gov) to produce energy, and it acts as an
[antioxidant](/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=English&dictionary=Cancer.gov).
- Coenzyme Q10 has shown an ability to stimulate the [immune
system](/Common/PopUps/popDefinition.aspx?id=46356&version=healthprofessional&language=English&dictionary=Cancer.gov) and to protect the heart from damage caused by certain
[chemotherapy](/Common/PopUps/popDefinition.aspx?id=45214&version=healthprofessional&language=English&dictionary=Cancer.gov) drugs.
- Low [blood](/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=English&dictionary=Cancer.gov) levels of coenzyme Q10 have been detected in
patients with some types of cancer.
- No report of a [randomized clinical trial](/Common/PopUps/popDefinition.aspx?id=45858&version=healthprofessional&language=English&dictionary=Cancer.gov)
of coenzyme Q10 as a treatment for cancer has been published in a
peer-reviewed scientific journal.
- Coenzyme Q10 is marketed in the United States as a [dietary
supplement](/Common/PopUps/popDefinition.aspx?id=373932&version=healthprofessional&language=English&dictionary=Cancer.gov).

Many of the medical and scientific terms used in the summary are hypertext linked (at first use in each section) to the [NCI Dictionary of Cancer Terms](https://www.cancer.gov/publications/dictionaries/cancer-terms/ "https://www.cancer.gov/publications/dictionaries/cancer-terms/"), which is oriented toward nonexperts. When a linked term is clicked, a definition will appear in a separate window.

Reference citations in some [PDQ](/Common/PopUps/popDefinition.aspx?id=44271&version=healthprofessional&language=English&dictionary=Cancer.gov) cancer information summaries may include links to external websites that are operated by individuals or organizations for the purpose of marketing or advocating the use of specific treatments or products. These reference citations are included for informational purposes only. Their inclusion should not be viewed as an endorsement of the content of the websites, or of any treatment or product, by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board or the [National Cancer Institute](/Common/PopUps/popDefinition.aspx?id=44266&version=healthprofessional&language=English&dictionary=Cancer.gov).

## General Information

[Coenzyme](/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=English&dictionary=Cancer.gov) Q10 (also known as CoQ10, Q10,
vitamin Q10, ubiquinone, and ubidecarenone) is a benzoquinone
compound synthesized naturally by the human body. The “Q” and the “10” in the
name refer to the quinone chemical group and the 10 isoprenyl subunits that are part of this compound’s structure. The term
“coenzyme” denotes it as an organic (contains carbon atoms), nonprotein [molecule](/Common/PopUps/popDefinition.aspx?id=45065&version=healthprofessional&language=English&dictionary=Cancer.gov) necessary for the proper
functioning of its [protein](/Common/PopUps/popDefinition.aspx?id=46092&version=healthprofessional&language=English&dictionary=Cancer.gov) partner (an [enzyme](/Common/PopUps/popDefinition.aspx?id=46081&version=healthprofessional&language=English&dictionary=Cancer.gov) or an enzyme complex). Coenzyme
Q10 is used by [cells](/Common/PopUps/popDefinition.aspx?id=46476&version=healthprofessional&language=English&dictionary=Cancer.gov) of the body in a process known variously as:

- [Aerobic respiration](/Common/PopUps/popDefinition.aspx?id=43993&version=healthprofessional&language=English&dictionary=Cancer.gov).
- [Aerobic metabolism](/Common/PopUps/popDefinition.aspx?id=43992&version=healthprofessional&language=English&dictionary=Cancer.gov).
- [Oxidative metabolism](/Common/PopUps/popDefinition.aspx?id=44071&version=healthprofessional&language=English&dictionary=Cancer.gov).
- [Cell respiration](/Common/PopUps/popDefinition.aspx?id=44008&version=healthprofessional&language=English&dictionary=Cancer.gov).

Through this
process, mitochondria produce energy for cell growth and maintenance.[[1](#cit/section_2.1)-[4](#cit/section_2.4)]
Coenzyme Q10 is also used by the body as an [endogenous](/Common/PopUps/popDefinition.aspx?id=44026&version=healthprofessional&language=English&dictionary=Cancer.gov) [antioxidant](/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=English&dictionary=Cancer.gov).[[1](#cit/section_2.1),[2](#cit/section_2.2),[4](#cit/section_2.4)-[8](#cit/section_2.8)] An antioxidant is a substance that protects cells from
[free radicals](/Common/PopUps/popDefinition.aspx?id=44030&version=healthprofessional&language=English&dictionary=Cancer.gov), which are highly
reactive chemicals, often containing oxygen atoms, capable of damaging
important cellular components such as [DNA](/Common/PopUps/popDefinition.aspx?id=44393&version=healthprofessional&language=English&dictionary=genetic) and [lipids](/Common/PopUps/popDefinition.aspx?id=46068&version=healthprofessional&language=English&dictionary=Cancer.gov). In addition, the [plasma](/Common/PopUps/popDefinition.aspx?id=45839&version=healthprofessional&language=English&dictionary=Cancer.gov) level of coenzyme Q10 has
been used in studies as a measure of [oxidative stress](/Common/PopUps/popDefinition.aspx?id=44072&version=healthprofessional&language=English&dictionary=Cancer.gov).[[9](#cit/section_2.9),[10](#cit/section_2.10)]

Coenzyme Q10 is present in most [tissues](/Common/PopUps/popDefinition.aspx?id=46683&version=healthprofessional&language=English&dictionary=Cancer.gov), but the highest
concentrations are found in the following organs:[[11](#cit/section_2.11)]

- Heart.
- [Liver](/Common/PopUps/popDefinition.aspx?id=46312&version=healthprofessional&language=English&dictionary=Cancer.gov).
- [Kidneys](/Common/PopUps/popDefinition.aspx?id=46325&version=healthprofessional&language=English&dictionary=Cancer.gov).
- [Pancreas](/Common/PopUps/popDefinition.aspx?id=46254&version=healthprofessional&language=English&dictionary=Cancer.gov).

The lowest concentration is
found in the [lungs](/Common/PopUps/popDefinition.aspx?id=270740&version=healthprofessional&language=English&dictionary=Cancer.gov).[[11](#cit/section_2.11)] Tissue levels of this compound decrease as people age,
due to increased requirements, decreased production,[[11](#cit/section_2.11)] or insufficient intake
of the chemical precursors needed for synthesis.[[12](#cit/section_2.12)] In humans,
normal [blood](/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=English&dictionary=Cancer.gov) levels of coenzyme Q10 have been defined variably,
with reported normal values ranging from 0.30 to 3.84 [µg](/Common/PopUps/popDefinition.aspx?id=306521&version=healthprofessional&language=English&dictionary=Cancer.gov)/[mL](/Common/PopUps/popDefinition.aspx?id=44214&version=healthprofessional&language=English&dictionary=Cancer.gov).[[2](#cit/section_2.2),[4](#cit/section_2.4),[13](#cit/section_2.13),[14](#cit/section_2.14)]

Given the importance of coenzyme Q10 in optimizing cellular energy
production, use of this compound as a treatment for diseases other than [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov)
has been explored. Most of these investigations have focused on coenzyme
Q10 as a treatment for [cardiovascular](/Common/PopUps/popDefinition.aspx?id=44005&version=healthprofessional&language=English&dictionary=Cancer.gov) disease.[[2](#cit/section_2.2),[4](#cit/section_2.4),[15](#cit/section_2.15)] In patients with cancer, coenzyme Q10 has been shown to do the following:

- Protect the heart from [anthracycline](/Common/PopUps/popDefinition.aspx?id=44916&version=healthprofessional&language=English&dictionary=Cancer.gov)-induced
[cardiotoxicity](/Common/PopUps/popDefinition.aspx?id=44004&version=healthprofessional&language=English&dictionary=Cancer.gov) (anthracyclines are
a family of [chemotherapy](/Common/PopUps/popDefinition.aspx?id=45214&version=healthprofessional&language=English&dictionary=Cancer.gov) drugs, including [doxorubicin](/Common/PopUps/popDefinition.aspx?id=560140&version=healthprofessional&language=English&dictionary=Cancer.gov), that have the potential to
damage the heart).[[3](#cit/section_2.3),[16](#cit/section_2.16)-[18](#cit/section_2.18)]
- Stimulate the [immune system](/Common/PopUps/popDefinition.aspx?id=46356&version=healthprofessional&language=English&dictionary=Cancer.gov).[[19](#cit/section_2.19),[20](#cit/section_2.20)]

Stimulation of the immune system by this compound has also been observed
in [animal studies](/Common/PopUps/popDefinition.aspx?id=454774&version=healthprofessional&language=English&dictionary=Cancer.gov) and in humans without cancer.[[21](#cit/section_2.21)-[27](#cit/section_2.27)] In part because of its
[immunostimulatory](/Common/PopUps/popDefinition.aspx?id=285968&version=healthprofessional&language=English&dictionary=Cancer.gov) potential, coenzyme Q10 has been used as an [adjuvant therapy](/Common/PopUps/popDefinition.aspx?id=45587&version=healthprofessional&language=English&dictionary=Cancer.gov) in patients with
various types of cancer.[[17](#cit/section_2.17),[20](#cit/section_2.20),[28](#cit/section_2.28)-[33](#cit/section_2.33)]

While coenzyme Q10 may show indirect anticancer activity through
its effect(s) on the immune system, there is evidence to suggest that
[analogs](/Common/PopUps/popDefinition.aspx?id=44919&version=healthprofessional&language=English&dictionary=Cancer.gov) of this compound can suppress
cancer growth directly. Analogs of coenzyme Q10 have been shown to
inhibit the [proliferation](/Common/PopUps/popDefinition.aspx?id=44572&version=healthprofessional&language=English&dictionary=Cancer.gov) of cancer cells *[in vitro](/Common/PopUps/popDefinition.aspx?id=45733&version=healthprofessional&language=English&dictionary=Cancer.gov)* and the growth of cancer cells
[transplanted](/Common/PopUps/popDefinition.aspx?id=46631&version=healthprofessional&language=English&dictionary=Cancer.gov) into rats and mice.[[12](#cit/section_2.12),[34](#cit/section_2.34)] In view of these findings, it has
been proposed that analogs of coenzyme Q10 may function as [antimetabolites](/Common/PopUps/popDefinition.aspx?id=45152&version=healthprofessional&language=English&dictionary=Cancer.gov) to disrupt normal
[biochemical reactions](/Common/PopUps/popDefinition.aspx?id=44124&version=healthprofessional&language=English&dictionary=Cancer.gov) that are required for cell growth and/or survival and,
thus, that they may be useful as [chemotherapeutic
agents](/Common/PopUps/popDefinition.aspx?id=44009&version=healthprofessional&language=English&dictionary=Cancer.gov).[[12](#cit/section_2.12),[34](#cit/section_2.34)]

Several companies distribute coenzyme Q10 as a [dietary
supplement](/Common/PopUps/popDefinition.aspx?id=373932&version=healthprofessional&language=English&dictionary=Cancer.gov). In the United States, dietary supplements are regulated by the [U.S. Food and Drug
Administration](/Common/PopUps/popDefinition.aspx?id=454785&version=healthprofessional&language=English&dictionary=Cancer.gov) (FDA) as a separate category from foods, cosmetics, and drugs. Unlike drugs, dietary supplements do not require premarket evaluation and approval by the FDA unless specific disease [prevention](/Common/PopUps/popDefinition.aspx?id=439419&version=healthprofessional&language=English&dictionary=Cancer.gov) or
treatment claims are made. The quality and amount of ingredients in dietary supplements are also regulated by the FDA through Good Manufacturing Practices (GMPs). The FDA GMPs requires that every finished batch of dietary supplement meets each product specification for identity, purity, strength, composition, and limits on contamination that may [adulterate](/Common/PopUps/popDefinition.aspx?id=686042&version=healthprofessional&language=English&dictionary=Cancer.gov) dietary supplements. Because dietary supplements are not formally
reviewed for manufacturing consistency every year, ingredients may vary considerably
from lot to lot and there is no guarantee that ingredients claimed on product labels are present (or are present in the specified amounts). The FDA has not approved coenzyme Q10 for the treatment of cancer or any other medical condition.

To conduct [clinical](/Common/PopUps/popDefinition.aspx?id=44168&version=healthprofessional&language=English&dictionary=Cancer.gov) drug research in the United States, researchers must
file an Investigational New Drug (IND) application with the FDA. The IND
application process is highly confidential, and IND information can be
disclosed only by the applicants. No investigators have announced
that they have applied for an IND to study coenzyme Q10 as a
treatment for cancer.

In animal studies, coenzyme Q10 has been administered by
[injection](/Common/PopUps/popDefinition.aspx?id=44678&version=healthprofessional&language=English&dictionary=Cancer.gov) ([intravenous](/Common/PopUps/popDefinition.aspx?id=46682&version=healthprofessional&language=English&dictionary=Cancer.gov),
[intraperitoneal](/Common/PopUps/popDefinition.aspx?id=46339&version=healthprofessional&language=English&dictionary=Cancer.gov),
[intramuscular](/Common/PopUps/popDefinition.aspx?id=44048&version=healthprofessional&language=English&dictionary=Cancer.gov), or
[subcutaneous](/Common/PopUps/popDefinition.aspx?id=45914&version=healthprofessional&language=English&dictionary=Cancer.gov)). In humans, it is
usually taken
[orally](/Common/PopUps/popDefinition.aspx?id=44068&version=healthprofessional&language=English&dictionary=Cancer.gov) as a pill (gel bead or [capsule](/Common/PopUps/popDefinition.aspx?id=455334&version=healthprofessional&language=English&dictionary=Cancer.gov)), but
intravenous [infusions](/Common/PopUps/popDefinition.aspx?id=45738&version=healthprofessional&language=English&dictionary=Cancer.gov) have been
given.[[4](#cit/section_2.4)] Coenzyme Q10 is absorbed best with fat; therefore, lipid
preparations are better absorbed than the purified compound.[[2](#cit/section_2.2),[4](#cit/section_2.4)]
In human studies, supplementation [doses](/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=English&dictionary=Cancer.gov) and administration schedules have
varied, but usually have been in the range of 90 to 390 [mg](/Common/PopUps/popDefinition.aspx?id=44213&version=healthprofessional&language=English&dictionary=Cancer.gov)/day.

###### References

1. Crane FL, Sun IL, Sun EE: The essential functions of coenzyme Q. Clin Investig 71 (8 Suppl): S55-9, 1993. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8241706&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8241706&dopt=Abstract")
2. Pepping J: Coenzyme Q10. Am J Health Syst Pharm 56 (6): 519-21, 1999. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10192685&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10192685&dopt=Abstract")
3. Folkers K, Wolaniuk A: Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp Clin Res 11 (8): 539-45, 1985. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3836873&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3836873&dopt=Abstract")
4. Overvad K, Diamant B, Holm L, et al.: Coenzyme Q10 in health and disease. Eur J Clin Nutr 53 (10): 764-70, 1999. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10556981&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10556981&dopt=Abstract")
5. Beyer RE, Nordenbrand K, Ernster L: The role of coenzyme Q as a mitochondrial antioxidant: a short review. In: Folkers K, Yamamura Y, eds.: Biomedical and Clinical Aspects of Coenzyme Q. Vol 5. Elsevier Science Publishers B V (Biomedical Division), 1986, pp 17-24.
6. Gordon M: Dietary antioxidants in disease prevention. Nat Prod Rep 13 (4): 265-73, 1996. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8760864&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8760864&dopt=Abstract")
7. Palazzoni G, Pucello D, Littarru GP, et al.: Coenzyme Q10 and colorectal neoplasms in aged patients. Rays 22 (1 Suppl): 73-6, 1997 Jan-Mar. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9250020&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9250020&dopt=Abstract")
8. Ernster L, Dallner G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1271 (1): 195-204, 1995. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7599208&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7599208&dopt=Abstract")
9. Yamamoto Y, Yamashita S, Fujisawa A, et al.: Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem Biophys Res Commun 247 (1): 166-70, 1998. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9636673&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9636673&dopt=Abstract")
10. Yamamoto Y, Yamashita S: Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress. Mol Aspects Med 18 (Suppl): S79-84, 1997. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9266509&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9266509&dopt=Abstract")
11. Ernster L, Forsmark-Andrée P: Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Investig 71 (8 Suppl): S60-5, 1993. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8241707&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8241707&dopt=Abstract")
12. Folkers K: The potential of coenzyme Q 10 (NSC-140865) in cancer treatment. Cancer Chemother Rep 2 4 (4): 19-22, 1974. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4218125&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4218125&dopt=Abstract")
13. Folkers K, Osterborg A, Nylander M, et al.: Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 234 (2): 296-9, 1997. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9177262&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9177262&dopt=Abstract")
14. Jolliet P, Simon N, Barré J, et al.: Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. Int J Clin Pharmacol Ther 36 (9): 506-9, 1998. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9760013&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9760013&dopt=Abstract")
15. Baggio E, Gandini R, Plancher AC, et al.: Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 15 (Suppl): s287-94, 1994. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752841&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752841&dopt=Abstract")
16. Cortes EP, Gupta M, Chou C, et al.: Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep 62 (6): 887-91, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=667863&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=667863&dopt=Abstract")
17. Folkers K, Brown R, Judy WV, et al.: Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Commun 192 (1): 241-5, 1993. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8476426&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8476426&dopt=Abstract")
18. Iarussi D, Auricchio U, Agretto A, et al.: Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med 15 (Suppl): s207-12, 1994. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752832&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752832&dopt=Abstract")
19. Folkers K, Shizukuishi S, Takemura K, et al.: Increase in levels of IgG in serum of patients treated with coenzyme Q10. Res Commun Chem Pathol Pharmacol 38 (2): 335-8, 1982. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7163631&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7163631&dopt=Abstract")
20. Complementary treatments highlighted at recent meeting. Oncology (Huntingt) 13 (2): 166, 1999. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10079467&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10079467&dopt=Abstract")
21. Bliznakov E, Casey A, Premuzic E: Coenzymes Q: stimulants of the phagocytic activity in rats and immune response in mice. Experientia 26 (9): 953-4, 1970. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5478631&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5478631&dopt=Abstract")
22. Folkers K, Hanioka T, Xia LJ, et al.: Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun 176 (2): 786-91, 1991. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1673841&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1673841&dopt=Abstract")
23. Kawase I, Niitani H, Saijo N, et al.: Enhancing effect of coenzyme, Q10 on immunorestoration with Mycobacterium bovis BCG in tumor-bearing mice. Gann 69 (4): 493-7, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=101414&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=101414&dopt=Abstract")
24. Bliznakov EG: Effect of stimulation of the host defense system by coenzyme Q 10 on dibenzpyrene-induced tumors and infection with Friend leukemia virus in mice. Proc Natl Acad Sci U S A 70 (2): 390-4, 1973. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4510283&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4510283&dopt=Abstract")
25. Bliznakov EG, Adler AD: Nonlinear response of the reticuloendothelial system upon stimulation. Pathol Microbiol (Basel) 38 (6): 393-410, 1972. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4346875&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4346875&dopt=Abstract")
26. Bliznakov EG: Coenzyme Q in experimental infections and neoplasia. In: Folkers K, Yamamura Y, eds.: Biomedical and Clinical Aspects of Coenzyme Q. Vol 1. Elsevier/North-Holland Biomedical Press, 1977, pp 73-83.
27. Barbieri B, Lund B, Lundström B, et al.: Coenzyme Q10 administration increases antibody titer in hepatitis B vaccinated volunteers--a single blind placebo-controlled and randomized clinical study. Biofactors 9 (2-4): 351-7, 1999. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10416052&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10416052&dopt=Abstract")
28. Lockwood K, Moesgaard S, Hanioka T, et al.: Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 15 (Suppl): s231-40, 1994. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752835&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752835&dopt=Abstract")
29. Lockwood K, Moesgaard S, Folkers K: Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 199 (3): 1504-8, 1994. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7908519&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7908519&dopt=Abstract")
30. Lockwood K, Moesgaard S, Yamamoto T, et al.: Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 212 (1): 172-7, 1995. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7612003&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7612003&dopt=Abstract")
31. Folkers K: Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy. Biochem Biophys Res Commun 224 (2): 358-61, 1996. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8702395&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8702395&dopt=Abstract")
32. Ren S, Lien EJ: Natural products and their derivatives as cancer chemopreventive agents. Prog Drug Res 48: 147-71, 1997. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9204686&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9204686&dopt=Abstract")
33. Hodges S, Hertz N, Lockwood K, et al.: CoQ10: could it have a role in cancer management? Biofactors 9 (2-4): 365-70, 1999. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10416054&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10416054&dopt=Abstract")
34. Folkers K, Porter TH, Bertino JR, et al.: Inhibition of two human tumor cell lines by antimetabolites of coenzyme Q10. Res Commun Chem Pathol Pharmacol 19 (3): 485-90, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=653103&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=653103&dopt=Abstract")

## History

[Coenzyme](/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=English&dictionary=Cancer.gov) Q10 was first isolated in 1957, and its
chemical structure (benzoquinone compound) was determined in 1958.[[1](#cit/section_3.1),[2](#cit/section_3.2)] Interest in coenzyme Q10 as a [therapeutic](/Common/PopUps/popDefinition.aspx?id=43985&version=healthprofessional&language=English&dictionary=Cancer.gov) agent in [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov)
began in 1961, when a [deficiency](/Common/PopUps/popDefinition.aspx?id=321364&version=healthprofessional&language=English&dictionary=Cancer.gov) was noted in the [blood](/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=English&dictionary=Cancer.gov) of both Swedish and
American cancer patients, especially in the blood of patients with [breast
cancer](/Common/PopUps/popDefinition.aspx?id=444971&version=healthprofessional&language=English&dictionary=Cancer.gov).[[2](#cit/section_3.2)-[4](#cit/section_3.4)] A subsequent [study](/Common/PopUps/popDefinition.aspx?id=44195&version=healthprofessional&language=English&dictionary=Cancer.gov) showed a [statistically
significant](/Common/PopUps/popDefinition.aspx?id=44167&version=healthprofessional&language=English&dictionary=Cancer.gov) relationship between the level of [plasma](/Common/PopUps/popDefinition.aspx?id=45839&version=healthprofessional&language=English&dictionary=Cancer.gov) coenzyme Q10
deficiency and breast cancer [prognosis](/Common/PopUps/popDefinition.aspx?id=45849&version=healthprofessional&language=English&dictionary=Cancer.gov).[[5](#cit/section_3.5)] Low blood levels of this
compound have been reported in patients with [malignancies](/Common/PopUps/popDefinition.aspx?id=45771&version=healthprofessional&language=English&dictionary=Cancer.gov) other than breast
cancer, including [myeloma](/Common/PopUps/popDefinition.aspx?id=45795&version=healthprofessional&language=English&dictionary=Cancer.gov), [lymphoma](/Common/PopUps/popDefinition.aspx?id=45368&version=healthprofessional&language=English&dictionary=Cancer.gov), and cancers of the [lung](/Common/PopUps/popDefinition.aspx?id=270740&version=healthprofessional&language=English&dictionary=Cancer.gov),
[prostate](/Common/PopUps/popDefinition.aspx?id=46539&version=healthprofessional&language=English&dictionary=Cancer.gov), [pancreas](/Common/PopUps/popDefinition.aspx?id=46254&version=healthprofessional&language=English&dictionary=Cancer.gov), [colon](/Common/PopUps/popDefinition.aspx?id=46462&version=healthprofessional&language=English&dictionary=Cancer.gov), [kidney](/Common/PopUps/popDefinition.aspx?id=46325&version=healthprofessional&language=English&dictionary=Cancer.gov), and [head and neck](/Common/PopUps/popDefinition.aspx?id=257519&version=healthprofessional&language=English&dictionary=Cancer.gov).[[2](#cit/section_3.2),[6](#cit/section_3.6),[7](#cit/section_3.7)]
Furthermore, decreased levels of coenzyme Q10 have been detected in
[malignant](/Common/PopUps/popDefinition.aspx?id=45772&version=healthprofessional&language=English&dictionary=Cancer.gov) human [tissue](/Common/PopUps/popDefinition.aspx?id=46683&version=healthprofessional&language=English&dictionary=Cancer.gov),[[8](#cit/section_3.8)-[12](#cit/section_3.12)] but
increased levels have been reported as well.[[8](#cit/section_3.8)]

A large amount of [laboratory](/Common/PopUps/popDefinition.aspx?id=44512&version=healthprofessional&language=English&dictionary=Cancer.gov) and [animal](/Common/PopUps/popDefinition.aspx?id=454774&version=healthprofessional&language=English&dictionary=Cancer.gov) data on coenzyme Q10 have
accumulated since 1962.[[2](#cit/section_3.2)] Research into cellular energy-producing mechanisms that involve this compound was awarded the Nobel Prize in
Chemistry in 1978. Some of the accumulated data show that coenzyme
Q10 stimulates animal [immune systems](/Common/PopUps/popDefinition.aspx?id=46356&version=healthprofessional&language=English&dictionary=Cancer.gov), leading to higher [antibody](/Common/PopUps/popDefinition.aspx?id=44918&version=healthprofessional&language=English&dictionary=Cancer.gov) levels,[[13](#cit/section_3.13)] greater numbers
and/or activities of [macrophages](/Common/PopUps/popDefinition.aspx?id=44054&version=healthprofessional&language=English&dictionary=Cancer.gov) and
[T cells](/Common/PopUps/popDefinition.aspx?id=44928&version=healthprofessional&language=English&dictionary=Cancer.gov) (T [lymphocytes](/Common/PopUps/popDefinition.aspx?id=45765&version=healthprofessional&language=English&dictionary=Cancer.gov)),[[13](#cit/section_3.13),[14](#cit/section_3.14)] and increased
resistance to [infection](/Common/PopUps/popDefinition.aspx?id=45364&version=healthprofessional&language=English&dictionary=Cancer.gov).[[15](#cit/section_3.15)-[17](#cit/section_3.17)] Coenzyme Q10 has also been
reported to increase IgG ([immunoglobulin](/Common/PopUps/popDefinition.aspx?id=45725&version=healthprofessional&language=English&dictionary=Cancer.gov) G) antibody levels
and to increase the CD4 to CD8 T-cell ratio in humans.[[18](#cit/section_3.18)-[20](#cit/section_3.20)] CD4 and CD8
are [proteins](/Common/PopUps/popDefinition.aspx?id=46092&version=healthprofessional&language=English&dictionary=Cancer.gov) found on the surface of T cells, with CD4 and CD8 identifying
[helper T cells](/Common/PopUps/popDefinition.aspx?id=44594&version=healthprofessional&language=English&dictionary=Cancer.gov) and [cytotoxic T cells](/Common/PopUps/popDefinition.aspx?id=45664&version=healthprofessional&language=English&dictionary=Cancer.gov),
respectively; decreased CD4 to CD8 T-cell ratios have been reported for cancer
patients.[[21](#cit/section_3.21),[22](#cit/section_3.22)] Research subsequently delineated the [antioxidant](/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=English&dictionary=Cancer.gov) properties
of coenzyme Q10.[[23](#cit/section_3.23)-[27](#cit/section_3.27)]

Proposed mechanisms of action for coenzyme Q10 that are relevant
to cancer include its essential function in cellular energy production and its
stimulation of the immune system (which may both be related), as well as
its role as an antioxidant. Coenzyme Q10 is essential to
[aerobic](/Common/PopUps/popDefinition.aspx?id=43991&version=healthprofessional&language=English&dictionary=Cancer.gov) energy production,[[1](#cit/section_3.1),[25](#cit/section_3.25),[28](#cit/section_3.28)] and it has been suggested that increased cellular energy leads to
increased antibody synthesis in [B cells](/Common/PopUps/popDefinition.aspx?id=45611&version=healthprofessional&language=English&dictionary=Cancer.gov)
([B lymphocytes](/Common/PopUps/popDefinition.aspx?id=44953&version=healthprofessional&language=English&dictionary=Cancer.gov)).[[6](#cit/section_3.6),[18](#cit/section_3.18)] As noted previously ([General Information section](/about-cancer/treatment/cam/hp/coenzyme-q10-pdq#_5)),
coenzyme Q10 can also behave as an antioxidant.[[1](#cit/section_3.1),[25](#cit/section_3.25)-[27](#cit/section_3.27),[29](#cit/section_3.29)-[32](#cit/section_3.32)] In this capacity, coenzyme Q10 is thought to stabilize cell
membranes ([lipid](/Common/PopUps/popDefinition.aspx?id=46068&version=healthprofessional&language=English&dictionary=Cancer.gov)-containing structures essential to maintaining cell
integrity) and to prevent [free radical](/Common/PopUps/popDefinition.aspx?id=44030&version=healthprofessional&language=English&dictionary=Cancer.gov) damage to other important cellular
components.[[1](#cit/section_3.1),[25](#cit/section_3.25),[27](#cit/section_3.27),[32](#cit/section_3.32)] Free radical damage to [DNA](/Common/PopUps/popDefinition.aspx?id=44393&version=healthprofessional&language=English&dictionary=genetic) (and possibly to
other cellular [molecules](/Common/PopUps/popDefinition.aspx?id=45065&version=healthprofessional&language=English&dictionary=Cancer.gov)) may be a factor in cancer development.[[11](#cit/section_3.11),[23](#cit/section_3.23),[30](#cit/section_3.30),[33](#cit/section_3.33)-[36](#cit/section_3.36)]

###### References

1. Pepping J: Coenzyme Q10. Am J Health Syst Pharm 56 (6): 519-21, 1999. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10192685&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10192685&dopt=Abstract")
2. Folkers K, Osterborg A, Nylander M, et al.: Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 234 (2): 296-9, 1997. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9177262&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9177262&dopt=Abstract")
3. Lockwood K, Moesgaard S, Yamamoto T, et al.: Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 212 (1): 172-7, 1995. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7612003&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7612003&dopt=Abstract")
4. Ren S, Lien EJ: Natural products and their derivatives as cancer chemopreventive agents. Prog Drug Res 48: 147-71, 1997. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9204686&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9204686&dopt=Abstract")
5. Jolliet P, Simon N, Barré J, et al.: Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. Int J Clin Pharmacol Ther 36 (9): 506-9, 1998. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9760013&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9760013&dopt=Abstract")
6. Folkers K: The potential of coenzyme Q 10 (NSC-140865) in cancer treatment. Cancer Chemother Rep 2 4 (4): 19-22, 1974. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4218125&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4218125&dopt=Abstract")
7. Folkers K: Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy. Biochem Biophys Res Commun 224 (2): 358-61, 1996. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8702395&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8702395&dopt=Abstract")
8. Chipperfield B: Ubiquinone concentrations in some tumour-bearing tissues. Ubiquinone concentrations in tumours and some normal tissues in man. Nature 209 (29): 1207-8, 1966. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5225398&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5225398&dopt=Abstract")
9. Eggens I, Elmberger PG, Löw P: Polyisoprenoid, cholesterol and ubiquinone levels in human hepatocellular carcinomas. Br J Exp Pathol 70 (1): 83-92, 1989. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2538136&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2538136&dopt=Abstract")
10. Mano T, Iwase K, Hayashi R, et al.: Vitamin E and coenzyme Q concentrations in the thyroid tissues of patients with various thyroid disorders. Am J Med Sci 315 (4): 230-2, 1998. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9537635&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9537635&dopt=Abstract")
11. Picardo M, Grammatico P, Roccella F, et al.: Imbalance in the antioxidant pool in melanoma cells and normal melanocytes from patients with melanoma. J Invest Dermatol 107 (3): 322-6, 1996. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8751964&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8751964&dopt=Abstract")
12. Portakal O, Ozkaya O, Erden Inal M, et al.: Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem 33 (4): 279-84, 2000. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10936586&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10936586&dopt=Abstract")
13. Bliznakov E, Casey A, Premuzic E: Coenzymes Q: stimulants of the phagocytic activity in rats and immune response in mice. Experientia 26 (9): 953-4, 1970. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5478631&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5478631&dopt=Abstract")
14. Kawase I, Niitani H, Saijo N, et al.: Enhancing effect of coenzyme, Q10 on immunorestoration with Mycobacterium bovis BCG in tumor-bearing mice. Gann 69 (4): 493-7, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=101414&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=101414&dopt=Abstract")
15. Bliznakov EG: Effect of stimulation of the host defense system by coenzyme Q 10 on dibenzpyrene-induced tumors and infection with Friend leukemia virus in mice. Proc Natl Acad Sci U S A 70 (2): 390-4, 1973. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4510283&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4510283&dopt=Abstract")
16. Bliznakov EG, Adler AD: Nonlinear response of the reticuloendothelial system upon stimulation. Pathol Microbiol (Basel) 38 (6): 393-410, 1972. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4346875&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4346875&dopt=Abstract")
17. Bliznakov EG: Coenzyme Q in experimental infections and neoplasia. In: Folkers K, Yamamura Y, eds.: Biomedical and Clinical Aspects of Coenzyme Q. Vol 1. Elsevier/North-Holland Biomedical Press, 1977, pp 73-83.
18. Folkers K, Shizukuishi S, Takemura K, et al.: Increase in levels of IgG in serum of patients treated with coenzyme Q10. Res Commun Chem Pathol Pharmacol 38 (2): 335-8, 1982. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7163631&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7163631&dopt=Abstract")
19. Folkers K, Hanioka T, Xia LJ, et al.: Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun 176 (2): 786-91, 1991. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1673841&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1673841&dopt=Abstract")
20. Barbieri B, Lund B, Lundström B, et al.: Coenzyme Q10 administration increases antibody titer in hepatitis B vaccinated volunteers--a single blind placebo-controlled and randomized clinical study. Biofactors 9 (2-4): 351-7, 1999. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10416052&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10416052&dopt=Abstract")
21. Shaw M, Ray P, Rubenstein M, et al.: Lymphocyte subsets in urologic cancer patients. Urol Res 15 (3): 181-5, 1987. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2957843&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2957843&dopt=Abstract")
22. Tsuyuguchi I, Shiratsuchi H, Fukuoka M: T-lymphocyte subsets in primary lung cancer. Jpn J Clin Oncol 17 (1): 13-7, 1987. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3494139&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3494139&dopt=Abstract")
23. Yamamoto Y, Yamashita S, Fujisawa A, et al.: Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem Biophys Res Commun 247 (1): 166-70, 1998. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9636673&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9636673&dopt=Abstract")
24. Yamamoto Y, Yamashita S: Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress. Mol Aspects Med 18 (Suppl): S79-84, 1997. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9266509&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9266509&dopt=Abstract")
25. Crane FL, Sun IL, Sun EE: The essential functions of coenzyme Q. Clin Investig 71 (8 Suppl): S55-9, 1993. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8241706&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8241706&dopt=Abstract")
26. Overvad K, Diamant B, Holm L, et al.: Coenzyme Q10 in health and disease. Eur J Clin Nutr 53 (10): 764-70, 1999. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10556981&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10556981&dopt=Abstract")
27. Ernster L, Forsmark-Andrée P: Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Investig 71 (8 Suppl): S60-5, 1993. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8241707&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8241707&dopt=Abstract")
28. Folkers K, Wolaniuk A: Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp Clin Res 11 (8): 539-45, 1985. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3836873&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3836873&dopt=Abstract")
29. Beyer RE, Nordenbrand K, Ernster L: The role of coenzyme Q as a mitochondrial antioxidant: a short review. In: Folkers K, Yamamura Y, eds.: Biomedical and Clinical Aspects of Coenzyme Q. Vol 5. Elsevier Science Publishers B V (Biomedical Division), 1986, pp 17-24.
30. Gordon M: Dietary antioxidants in disease prevention. Nat Prod Rep 13 (4): 265-73, 1996. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8760864&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8760864&dopt=Abstract")
31. Palazzoni G, Pucello D, Littarru GP, et al.: Coenzyme Q10 and colorectal neoplasms in aged patients. Rays 22 (1 Suppl): 73-6, 1997 Jan-Mar. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9250020&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9250020&dopt=Abstract")
32. Ernster L, Dallner G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1271 (1): 195-204, 1995. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7599208&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7599208&dopt=Abstract")
33. Aust AE, Eveleigh JF: Mechanisms of DNA oxidation. Proc Soc Exp Biol Med 222 (3): 246-52, 1999. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10601883&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10601883&dopt=Abstract")
34. Halliwell B: Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: measurement, mechanism and the effects of nutrition. Mutat Res 443 (1-2): 37-52, 1999. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10415430&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10415430&dopt=Abstract")
35. Burcham PC: Internal hazards: baseline DNA damage by endogenous products of normal metabolism. Mutat Res 443 (1-2): 11-36, 1999. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10415429&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10415429&dopt=Abstract")
36. Dreher D, Junod AF: Role of oxygen free radicals in cancer development. Eur J Cancer 32A (1): 30-8, 1996. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8695238&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8695238&dopt=Abstract")

## Laboratory/Animal/Preclinical Studies

[Laboratory](/Common/PopUps/popDefinition.aspx?id=44512&version=healthprofessional&language=English&dictionary=Cancer.gov) work on [coenzyme](/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=English&dictionary=Cancer.gov) Q10 has focused primarily on its
structure and its function in [cell respiration](/Common/PopUps/popDefinition.aspx?id=44008&version=healthprofessional&language=English&dictionary=Cancer.gov). Studies in [animals](/Common/PopUps/popDefinition.aspx?id=454774&version=healthprofessional&language=English&dictionary=Cancer.gov) have
demonstrated that coenzyme Q10 is capable of stimulating the [immune
system](/Common/PopUps/popDefinition.aspx?id=46356&version=healthprofessional&language=English&dictionary=Cancer.gov), with treated animals showing increased resistance to [protozoal](/Common/PopUps/popDefinition.aspx?id=44080&version=healthprofessional&language=English&dictionary=Cancer.gov) [infections](/Common/PopUps/popDefinition.aspx?id=45364&version=healthprofessional&language=English&dictionary=Cancer.gov) [[1](#cit/section_4.1),[2](#cit/section_4.2)] and to [viral](/Common/PopUps/popDefinition.aspx?id=44629&version=healthprofessional&language=English&dictionary=Cancer.gov)
and chemically-induced [neoplasia](/Common/PopUps/popDefinition.aspx?id=45801&version=healthprofessional&language=English&dictionary=Cancer.gov).[[1](#cit/section_4.1)-[4](#cit/section_4.4)] Early
studies of coenzyme Q10 showed increased [hematopoiesis](/Common/PopUps/popDefinition.aspx?id=44035&version=healthprofessional&language=English&dictionary=Cancer.gov) (the formation of new
[blood](/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=English&dictionary=Cancer.gov) cells) in monkeys,[[4](#cit/section_4.4),[5](#cit/section_4.5)] rabbits,[[6](#cit/section_4.6)] and
poultry.[[5](#cit/section_4.5)] Coenzyme Q10 demonstrated a protective
effect on the heart muscle of mice, rats, and rabbits given the [anthracycline](/Common/PopUps/popDefinition.aspx?id=44916&version=healthprofessional&language=English&dictionary=Cancer.gov)
anticancer drug [doxorubicin](/Common/PopUps/popDefinition.aspx?id=560140&version=healthprofessional&language=English&dictionary=Cancer.gov).[[7](#cit/section_4.7)-[12](#cit/section_4.12)] Although another study confirmed this
protective effect with [intraperitoneal](/Common/PopUps/popDefinition.aspx?id=46339&version=healthprofessional&language=English&dictionary=Cancer.gov) administration of doxorubicin in mice,
it failed to demonstrate a protective effect when the anthracycline was given
[intravenously](/Common/PopUps/popDefinition.aspx?id=46682&version=healthprofessional&language=English&dictionary=Cancer.gov), which is the route of administration in humans.[[13](#cit/section_4.13)]

Researchers in one study sounded a cautionary note when they found that
coadministration of coenzyme Q10 and [radiation therapy](/Common/PopUps/popDefinition.aspx?id=44971&version=healthprofessional&language=English&dictionary=Cancer.gov) decreased the
effectiveness of the radiation therapy.[[14](#cit/section_4.14)] In this study, mice inoculated with
human [small cell lung cancer](/Common/PopUps/popDefinition.aspx?id=45327&version=healthprofessional&language=English&dictionary=Cancer.gov) cells
(a [xenograft](/Common/PopUps/popDefinition.aspx?id=44095&version=healthprofessional&language=English&dictionary=Cancer.gov) study), and then given
coenzyme Q10 and single-[dose](/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=English&dictionary=Cancer.gov) radiation therapy, showed
substantially less inhibition of [tumor](/Common/PopUps/popDefinition.aspx?id=46634&version=healthprofessional&language=English&dictionary=Cancer.gov) growth than mice in the [control group](/Common/PopUps/popDefinition.aspx?id=44149&version=healthprofessional&language=English&dictionary=Cancer.gov)
that were treated with radiation therapy alone. Since radiation leads to the
production of [free radicals](/Common/PopUps/popDefinition.aspx?id=44030&version=healthprofessional&language=English&dictionary=Cancer.gov), and since [antioxidants](/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=English&dictionary=Cancer.gov) protect against free
radical damage, the effect in this study might be explained by coenzyme
Q10 acting as an antioxidant. As noted previously, there is some evidence from
laboratory and animal studies that [analogs](/Common/PopUps/popDefinition.aspx?id=44919&version=healthprofessional&language=English&dictionary=Cancer.gov) of coenzyme Q10 may
have direct anticancer activity.[[15](#cit/section_4.15),[16](#cit/section_4.16)] See the [General Information](/about-cancer/treatment/cam/hp/coenzyme-q10-pdq#_5) section.

###### References

1. Bliznakov EG, Adler AD: Nonlinear response of the reticuloendothelial system upon stimulation. Pathol Microbiol (Basel) 38 (6): 393-410, 1972. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4346875&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4346875&dopt=Abstract")
2. Bliznakov EG: Coenzyme Q in experimental infections and neoplasia. In: Folkers K, Yamamura Y, eds.: Biomedical and Clinical Aspects of Coenzyme Q. Vol 1. Elsevier/North-Holland Biomedical Press, 1977, pp 73-83.
3. Bliznakov EG: Effect of stimulation of the host defense system by coenzyme Q 10 on dibenzpyrene-induced tumors and infection with Friend leukemia virus in mice. Proc Natl Acad Sci U S A 70 (2): 390-4, 1973. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4510283&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4510283&dopt=Abstract")
4. Folkers K, Osterborg A, Nylander M, et al.: Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 234 (2): 296-9, 1997. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9177262&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9177262&dopt=Abstract")
5. Folkers K, Brown R, Judy WV, et al.: Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Commun 192 (1): 241-5, 1993. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8476426&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8476426&dopt=Abstract")
6. Ludwig FC, Elashoff RM, Smith JL, et al.: Response of the bone marrow of the vitamin E-deficient rabbit to coenzyme Q and vitamin E. Scand J Haematol 4 (4): 292-300, 1967. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6078061&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6078061&dopt=Abstract")
7. Choe JY, Combs AB, Folkers K: Prevention by coenzyme Q10 of the electrocardiographic changes induced by adriamycin in rats. Res Commun Chem Pathol Pharmacol 23 (1): 199-202, 1979. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=441512&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=441512&dopt=Abstract")
8. Combs AB, Choe JY, Truong DH, et al.: Reduction by coenzyme Q10 of the acute toxicity of adriamycin in mice. Res Commun Chem Pathol Pharmacol 18 (3): 565-8, 1977. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=928953&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=928953&dopt=Abstract")
9. Folkers K, Choe JY, Combs AB: Rescue by coenzyme Q10 from electrocardiographic abnormalities caused by the toxicity of adriamycin in the rat. Proc Natl Acad Sci U S A 75 (10): 5178-80, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=283424&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=283424&dopt=Abstract")
10. Lubawy WC, Dallam RA, Hurley LH: Protection against anthramycin-induced toxicity in mice by coenzyme Q10. J Natl Cancer Inst 64 (1): 105-9, 1980. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6928034&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6928034&dopt=Abstract")
11. Shinozawa S, Gomita Y, Araki Y: Protective effects of various drugs on adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice and rats. Biol Pharm Bull 16 (11): 1114-7, 1993. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8312867&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8312867&dopt=Abstract")
12. Usui T, Ishikura H, Izumi Y, et al.: Possible prevention from the progression of cardiotoxicity in adriamycin-treated rabbits by coenzyme Q10. Toxicol Lett 12 (1): 75-82, 1982. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7112605&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7112605&dopt=Abstract")
13. Shaeffer J, El-Mahdi AM, Nichols RK: Coenzyme Q10 and adriamycin toxicity in mice. Res Commun Chem Pathol Pharmacol 29 (2): 309-15, 1980. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7414051&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7414051&dopt=Abstract")
14. Lund EL, Quistorff B, Spang-Thomsen M, et al.: Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake. Folia Microbiol (Praha) 43 (5): 505-6, 1998. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9821311&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9821311&dopt=Abstract")
15. Folkers K: The potential of coenzyme Q 10 (NSC-140865) in cancer treatment. Cancer Chemother Rep 2 4 (4): 19-22, 1974. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4218125&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4218125&dopt=Abstract")
16. Folkers K, Porter TH, Bertino JR, et al.: Inhibition of two human tumor cell lines by antimetabolites of coenzyme Q10. Res Commun Chem Pathol Pharmacol 19 (3): 485-90, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=653103&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=653103&dopt=Abstract")

## Human/Clinical Studies

[Clinical studies](/Common/PopUps/popDefinition.aspx?id=44195&version=healthprofessional&language=English&dictionary=Cancer.gov) on the use of coenzyme Q10 to prevent [side effects](/Common/PopUps/popDefinition.aspx?id=46580&version=healthprofessional&language=English&dictionary=Cancer.gov) of [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov) treatment, treat side effects of cancer treatment, and/or as a treatment for cancer are very limited. Importantly, [clinical trials](/Common/PopUps/popDefinition.aspx?id=45961&version=healthprofessional&language=English&dictionary=Cancer.gov) that examined the use of coenzyme Q10 during cancer treatment to prevent toxicities have not followed patients for long-term outcomes to determine whether coenzyme Q10 decreased the [efficacy](/Common/PopUps/popDefinition.aspx?id=346517&version=healthprofessional&language=English&dictionary=Cancer.gov) of cancer treatments (e.g., [chemotherapy](/Common/PopUps/popDefinition.aspx?id=45214&version=healthprofessional&language=English&dictionary=Cancer.gov) and [radiation therapy)](/Common/PopUps/popDefinition.aspx?id=44971&version=healthprofessional&language=English&dictionary=Cancer.gov). A recent [observational study](/Common/PopUps/popDefinition.aspx?id=286105&version=healthprofessional&language=English&dictionary=Cancer.gov) conducted with 1,134 patients with [breast cancer](/Common/PopUps/popDefinition.aspx?id=444971&version=healthprofessional&language=English&dictionary=Cancer.gov) enrolled in an [National Cancer Institute](/Common/PopUps/popDefinition.aspx?id=44266&version=healthprofessional&language=English&dictionary=Cancer.gov) multi-institution clinical trial ([SWOG S0221](/clinicaltrials/NCT00070564)) suggested that the use of [antioxidant](/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=English&dictionary=Cancer.gov) supplements, including coenzyme Q10, prior to and during cancer treatment may be associated with increased [recurrence](/Common/PopUps/popDefinition.aspx?id=45861&version=healthprofessional&language=English&dictionary=Cancer.gov) rates and decreased survival.[[1](#cit/section_5.1)]

### Symptom and Side Effect Management

#### Cardiac toxicity

In view of promising results from [animal studies](/Common/PopUps/popDefinition.aspx?id=454774&version=healthprofessional&language=English&dictionary=Cancer.gov), coenzyme
Q10 was tested as a protective agent against [cardiac](/Common/PopUps/popDefinition.aspx?id=45634&version=healthprofessional&language=English&dictionary=Cancer.gov) toxicity that was observed in cancer
patients treated with the [anthracycline](/Common/PopUps/popDefinition.aspx?id=44916&version=healthprofessional&language=English&dictionary=Cancer.gov) drug [doxorubicin](/Common/PopUps/popDefinition.aspx?id=560140&version=healthprofessional&language=English&dictionary=Cancer.gov). It has been
postulated that doxorubicin interferes with energy-generating [biochemical
reactions](/Common/PopUps/popDefinition.aspx?id=44124&version=healthprofessional&language=English&dictionary=Cancer.gov) that involve coenzyme Q10 in heart muscle [mitochondria](/Common/PopUps/popDefinition.aspx?id=44060&version=healthprofessional&language=English&dictionary=Cancer.gov)
and that this interference can be overcome by coenzyme Q10 [supplementation](/Common/PopUps/popDefinition.aspx?id=45916&version=healthprofessional&language=English&dictionary=Cancer.gov).[[2](#cit/section_5.2)-[4](#cit/section_5.4)] Studies with adults and children, including the
aforementioned [randomized trial](/Common/PopUps/popDefinition.aspx?id=45858&version=healthprofessional&language=English&dictionary=Cancer.gov), have confirmed the decrease in cardiac
toxicity observed in animal studies.[[2](#cit/section_5.2),[5](#cit/section_5.5)-[7](#cit/section_5.7)] A randomized trial [[7](#cit/section_5.7)] of 20 patients tested the ability of coenzyme Q10 to reduce [cardiotoxicity](/Common/PopUps/popDefinition.aspx?id=44004&version=healthprofessional&language=English&dictionary=Cancer.gov) caused by anthracycline drugs.

#### Fatigue

Two randomized, [controlled trials](/Common/PopUps/popDefinition.aspx?id=44014&version=healthprofessional&language=English&dictionary=Cancer.gov) have explored the potential of coenzyme Q10-containing supplements to prevent or treat [fatigue](/Common/PopUps/popDefinition.aspx?id=321374&version=healthprofessional&language=English&dictionary=Cancer.gov) in patients who received cancer therapy. A randomized, [placebo-controlled](/Common/PopUps/popDefinition.aspx?id=44840&version=healthprofessional&language=English&dictionary=Cancer.gov) trial of 236 patients with breast cancer who received [adjuvant chemotherapy](/Common/PopUps/popDefinition.aspx?id=45587&version=healthprofessional&language=English&dictionary=Cancer.gov) with or without radiation therapy concluded that coenzyme Q10 at a daily [dose](/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=English&dictionary=Cancer.gov) of 300 [mg](/Common/PopUps/popDefinition.aspx?id=44213&version=healthprofessional&language=English&dictionary=Cancer.gov) combined with 300 [IU](/Common/PopUps/popDefinition.aspx?id=44764&version=healthprofessional&language=English&dictionary=Cancer.gov) of [vitamin E](/Common/PopUps/popDefinition.aspx?id=45023&version=healthprofessional&language=English&dictionary=Cancer.gov), divided into three doses, did not prevent treatment-induced worsening of mean fatigue levels or [quality of life](/Common/PopUps/popDefinition.aspx?id=45417&version=healthprofessional&language=English&dictionary=Cancer.gov) after 24 weeks of supplementation.[[8](#cit/section_5.8)] Another smaller trial (N = 59) used a daily [administration](/Common/PopUps/popDefinition.aspx?id=478733&version=healthprofessional&language=English&dictionary=Cancer.gov) of a different supplement that contained coenzyme Q10 (30 mg) along with branched-chain [amino acids](/Common/PopUps/popDefinition.aspx?id=446104&version=healthprofessional&language=English&dictionary=Cancer.gov) (2,500 mg) and [L-carnitine](/Common/PopUps/popDefinition.aspx?id=321377&version=healthprofessional&language=English&dictionary=Cancer.gov) (50 mg). All patients received adjuvant chemotherapy, but none received radiation therapy during the 21 days of the trial. The results of this trial also failed to show a significant difference in the mean fatigue levels between the treatment group and the [control group](/Common/PopUps/popDefinition.aspx?id=44149&version=healthprofessional&language=English&dictionary=Cancer.gov), though a [statistically significant](/Common/PopUps/popDefinition.aspx?id=44167&version=healthprofessional&language=English&dictionary=Cancer.gov) benefit was seen for the study’s [primary endpoint](/Common/PopUps/popDefinition.aspx?id=44163&version=healthprofessional&language=English&dictionary=Cancer.gov) (worst level of fatigue during the past 24 hours).[[9](#cit/section_5.9)]

### Cancer Treatment

The use of [coenzyme](/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=English&dictionary=Cancer.gov) Q10 as a treatment for cancer in humans has
been investigated in only a limited manner. In view of observations that [blood](/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=English&dictionary=Cancer.gov) levels of coenzyme
Q10 are frequently reduced in cancer patients,[[10](#cit/section_5.10)-[14](#cit/section_5.14)] supplementation with this [compound](/Common/PopUps/popDefinition.aspx?id=422394&version=healthprofessional&language=English&dictionary=Cancer.gov) has been tested in patients
undergoing [conventional treatment](/Common/PopUps/popDefinition.aspx?id=44950&version=healthprofessional&language=English&dictionary=Cancer.gov). An open-label, [nonblinded](/Common/PopUps/popDefinition.aspx?id=44066&version=healthprofessional&language=English&dictionary=Cancer.gov), uncontrolled clinical study
in Denmark followed 32 patients with breast cancer for 18 months.[[15](#cit/section_5.15)] The disease
had spread to the [axillary lymph nodes](/Common/PopUps/popDefinition.aspx?id=45607&version=healthprofessional&language=English&dictionary=Cancer.gov), and an
unreported number of patients had distant [metastases](/Common/PopUps/popDefinition.aspx?id=46710&version=healthprofessional&language=English&dictionary=Cancer.gov). Patients received
antioxidant supplementation ([vitamin C](/Common/PopUps/popDefinition.aspx?id=439435&version=healthprofessional&language=English&dictionary=Cancer.gov), vitamin E, and [beta carotene](/Common/PopUps/popDefinition.aspx?id=45328&version=healthprofessional&language=English&dictionary=Cancer.gov)), other
[vitamins](/Common/PopUps/popDefinition.aspx?id=44744&version=healthprofessional&language=English&dictionary=Cancer.gov) and trace [minerals](/Common/PopUps/popDefinition.aspx?id=45787&version=healthprofessional&language=English&dictionary=Cancer.gov), essential [fatty acids](/Common/PopUps/popDefinition.aspx?id=45689&version=healthprofessional&language=English&dictionary=Cancer.gov), and coenzyme
Q10 (at a dose of 90 mg/day), in addition to [standard
therapy](/Common/PopUps/popDefinition.aspx?id=44930&version=healthprofessional&language=English&dictionary=Cancer.gov) ([surgery](/Common/PopUps/popDefinition.aspx?id=45570&version=healthprofessional&language=English&dictionary=Cancer.gov), radiation therapy, and chemotherapy, with or without [tamoxifen](/Common/PopUps/popDefinition.aspx?id=509341&version=healthprofessional&language=English&dictionary=Cancer.gov)). Patients were seen every
3 months to [monitor](/Common/PopUps/popDefinition.aspx?id=454803&version=healthprofessional&language=English&dictionary=Cancer.gov) disease status ([progressive disease](/Common/PopUps/popDefinition.aspx?id=45850&version=healthprofessional&language=English&dictionary=Cancer.gov) or [recurrence](/Common/PopUps/popDefinition.aspx?id=45861&version=healthprofessional&language=English&dictionary=Cancer.gov)), and if there was a
suspicion of recurrence, [mammography](/Common/PopUps/popDefinition.aspx?id=45996&version=healthprofessional&language=English&dictionary=Cancer.gov), [bone scan](/Common/PopUps/popDefinition.aspx?id=46499&version=healthprofessional&language=English&dictionary=Cancer.gov), [x-ray](/Common/PopUps/popDefinition.aspx?id=45944&version=healthprofessional&language=English&dictionary=Cancer.gov), or [biopsy](/Common/PopUps/popDefinition.aspx?id=45164&version=healthprofessional&language=English&dictionary=Cancer.gov) was performed. The [survival rate](/Common/PopUps/popDefinition.aspx?id=44301&version=healthprofessional&language=English&dictionary=Cancer.gov) for
the study period was 100% (four deaths were expected). Six
patients were reported to show some evidence of [remission](/Common/PopUps/popDefinition.aspx?id=45867&version=healthprofessional&language=English&dictionary=Cancer.gov); however, incomplete clinical
data were provided and information suggestive of remission was presented for
only three of six patients. None of the six patients had evidence of
further metastases. For all 32 patients, decreased use of painkillers,
improved [quality of life](/Common/PopUps/popDefinition.aspx?id=45417&version=healthprofessional&language=English&dictionary=Cancer.gov), and an
absence of weight loss were reported. Whether painkiller use and quality of
life were measured objectively (e.g., from pharmacy records and validated
questionnaires, respectively) or subjectively (from patient self-reports) was
not specified.

In a [follow-up](/Common/PopUps/popDefinition.aspx?id=44671&version=healthprofessional&language=English&dictionary=Cancer.gov) study, one of six patients with a reported remission and
one new patient were treated for several months with higher doses of coenzyme
Q10 (390 mg/day and 300 mg/day, respectively).[[16](#cit/section_5.16)] Surgical
removal of the [primary](/Common/PopUps/popDefinition.aspx?id=45847&version=healthprofessional&language=English&dictionary=Cancer.gov) breast tumor in both patients had been incomplete.
After 3 to 4 months of high-level coenzyme Q10 supplementation,
both patients appeared to experience complete
[regression](/Common/PopUps/popDefinition.aspx?id=46039&version=healthprofessional&language=English&dictionary=Cancer.gov) of their [residual](/Common/PopUps/popDefinition.aspx?id=45869&version=healthprofessional&language=English&dictionary=Cancer.gov) breast
tumors (assessed by clinical examination and mammography). It should be noted
that a different patient identifier was used in the follow-up study for the
patient who had participated in the original study. Therefore, it is
impossible to determine which of the six patients with a reported remission
took part in the follow-up study. In the follow-up study report, the
researchers noted that all 32 patients from the original study remained alive
at 24 months of [observation](/Common/PopUps/popDefinition.aspx?id=45981&version=healthprofessional&language=English&dictionary=Cancer.gov), whereas six deaths had been expected.[[16](#cit/section_5.16)]

In another report by the same [investigators](/Common/PopUps/popDefinition.aspx?id=44685&version=healthprofessional&language=English&dictionary=Cancer.gov), three patients with breast cancer
who received high-dose coenzyme Q10
(390 mg/day) were followed for a total of 3 to 5 years.[[11](#cit/section_5.11)] One patient had [complete remission](/Common/PopUps/popDefinition.aspx?id=45651&version=healthprofessional&language=English&dictionary=Cancer.gov) of [liver metastases](/Common/PopUps/popDefinition.aspx?id=45316&version=healthprofessional&language=English&dictionary=Cancer.gov) (determined by clinical examination and [ultrasonography](/Common/PopUps/popDefinition.aspx?id=45557&version=healthprofessional&language=English&dictionary=Cancer.gov)), one patient had
remission of a tumor that had spread to the [chest wall](/Common/PopUps/popDefinition.aspx?id=44996&version=healthprofessional&language=English&dictionary=Cancer.gov) (determined by clinical
examination and [chest x-ray](/Common/PopUps/popDefinition.aspx?id=304687&version=healthprofessional&language=English&dictionary=Cancer.gov)), and one patient had no [microscopic](/Common/PopUps/popDefinition.aspx?id=44608&version=healthprofessional&language=English&dictionary=Cancer.gov)
evidence of remaining tumor after a [mastectomy](/Common/PopUps/popDefinition.aspx?id=45777&version=healthprofessional&language=English&dictionary=Cancer.gov) (determined by biopsy of the
tumor bed).

All three of the above-mentioned human studies [[11](#cit/section_5.11),[15](#cit/section_5.15),[16](#cit/section_5.16)] had important design
flaws that could have influenced their outcome. Study weaknesses include the
absence of a control group (i.e., all patients received coenzyme
Q10), possible [selection
bias](/Common/PopUps/popDefinition.aspx?id=44087&version=healthprofessional&language=English&dictionary=Cancer.gov) in the follow-up investigations, and multiple confounding variables
(i.e., patients received a variety of supplements in addition to coenzyme
Q10 and received standard therapy either during or
immediately before supplementation with coenzyme Q10). Thus, it is
impossible to determine whether any of the beneficial results was directly
related to coenzyme Q10 therapy.

[Anecdotal reports](/Common/PopUps/popDefinition.aspx?id=43995&version=healthprofessional&language=English&dictionary=Cancer.gov) of coenzyme Q10 lengthening the survival of
patients with [pancreatic](/Common/PopUps/popDefinition.aspx?id=44074&version=healthprofessional&language=English&dictionary=Cancer.gov), [lung](/Common/PopUps/popDefinition.aspx?id=270740&version=healthprofessional&language=English&dictionary=Cancer.gov), [rectal](/Common/PopUps/popDefinition.aspx?id=44083&version=healthprofessional&language=English&dictionary=Cancer.gov), [laryngeal](/Common/PopUps/popDefinition.aspx?id=46317&version=healthprofessional&language=English&dictionary=Cancer.gov), [colon](/Common/PopUps/popDefinition.aspx?id=46462&version=healthprofessional&language=English&dictionary=Cancer.gov), and [prostate](/Common/PopUps/popDefinition.aspx?id=46539&version=healthprofessional&language=English&dictionary=Cancer.gov) cancers
also exist in the peer-reviewed scientific literature.[[6](#cit/section_5.6)] The patients
described in these reports also received therapies other than coenzyme
Q10, including chemotherapy, radiation therapy, and surgery.

### Current Clinical Trials

Use our [advanced clinical trial search](https://www.cancer.gov/research/participate/clinical-trials-search/advanced "https://www.cancer.gov/research/participate/clinical-trials-search/advanced") to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. [General information](https://www.cancer.gov/research/participate/clinical-trials "https://www.cancer.gov/research/participate/clinical-trials") about clinical trials is also available.

###### References

1. Ambrosone CB, Zirpoli GR, Hutson AD, et al.: Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol 38 (8): 804-814, 2020. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31855498&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31855498&dopt=Abstract")
2. Cortes EP, Gupta M, Chou C, et al.: Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep 62 (6): 887-91, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=667863&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=667863&dopt=Abstract")
3. Usui T, Ishikura H, Izumi Y, et al.: Possible prevention from the progression of cardiotoxicity in adriamycin-treated rabbits by coenzyme Q10. Toxicol Lett 12 (1): 75-82, 1982. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7112605&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7112605&dopt=Abstract")
4. Iwamoto Y, Hansen IL, Porter TH, et al.: Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxidase, by adriamycin and other quinones having antitumor activity. Biochem Biophys Res Commun 58 (3): 633-8, 1974. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4152017&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4152017&dopt=Abstract")
5. Folkers K, Wolaniuk A: Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp Clin Res 11 (8): 539-45, 1985. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3836873&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3836873&dopt=Abstract")
6. Folkers K, Brown R, Judy WV, et al.: Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Commun 192 (1): 241-5, 1993. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8476426&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8476426&dopt=Abstract")
7. Iarussi D, Auricchio U, Agretto A, et al.: Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med 15 (Suppl): s207-12, 1994. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752832&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752832&dopt=Abstract")
8. Lesser GJ, Case D, Stark N, et al.: A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol 11 (1): 31-42, 2013. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22682875&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22682875&dopt=Abstract")
9. Iwase S, Kawaguchi T, Yotsumoto D, et al.: Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01). Support Care Cancer 24 (2): 637-646, 2016. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26105516&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26105516&dopt=Abstract")
10. Folkers K, Osterborg A, Nylander M, et al.: Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 234 (2): 296-9, 1997. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9177262&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9177262&dopt=Abstract")
11. Lockwood K, Moesgaard S, Yamamoto T, et al.: Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 212 (1): 172-7, 1995. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7612003&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7612003&dopt=Abstract")
12. Folkers K: Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy. Biochem Biophys Res Commun 224 (2): 358-61, 1996. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8702395&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8702395&dopt=Abstract")
13. Ren S, Lien EJ: Natural products and their derivatives as cancer chemopreventive agents. Prog Drug Res 48: 147-71, 1997. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9204686&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9204686&dopt=Abstract")
14. Shidal C, Yoon HS, Zheng W, et al.: Prospective study of plasma levels of coenzyme Q10 and lung cancer risk in a low-income population in the Southeastern United States. Cancer Med 10 (4): 1439-1447, 2021. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33547884&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33547884&dopt=Abstract")
15. Lockwood K, Moesgaard S, Hanioka T, et al.: Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 15 (Suppl): s231-40, 1994. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752835&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752835&dopt=Abstract")
16. Lockwood K, Moesgaard S, Folkers K: Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 199 (3): 1504-8, 1994. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7908519&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7908519&dopt=Abstract")

## Adverse Effects

No serious [toxicity](/Common/PopUps/popDefinition.aspx?id=43986&version=healthprofessional&language=English&dictionary=Cancer.gov) associated with the use of [coenzyme](/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=English&dictionary=Cancer.gov) Q10 has
been reported.[[1](#cit/section_6.1)-[4](#cit/section_6.4)] [Doses](/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=English&dictionary=Cancer.gov) of 100 [mg](/Common/PopUps/popDefinition.aspx?id=44213&version=healthprofessional&language=English&dictionary=Cancer.gov)/day or
higher have caused mild [insomnia](/Common/PopUps/popDefinition.aspx?id=44043&version=healthprofessional&language=English&dictionary=Cancer.gov) in
some individuals. [Liver](/Common/PopUps/popDefinition.aspx?id=46312&version=healthprofessional&language=English&dictionary=Cancer.gov) [enzyme](/Common/PopUps/popDefinition.aspx?id=46081&version=healthprofessional&language=English&dictionary=Cancer.gov) elevation has been detected in
patients taking doses of 300 mg/day for extended periods of time,
but no liver toxicity has been reported.[[1](#cit/section_6.1)] Researchers in one
[cardiovascular](/Common/PopUps/popDefinition.aspx?id=44005&version=healthprofessional&language=English&dictionary=Cancer.gov) [study](/Common/PopUps/popDefinition.aspx?id=44195&version=healthprofessional&language=English&dictionary=Cancer.gov) reported that coenzyme Q10 caused rashes,
[nausea](/Common/PopUps/popDefinition.aspx?id=390302&version=healthprofessional&language=English&dictionary=Cancer.gov), and [epigastric](/Common/PopUps/popDefinition.aspx?id=44027&version=healthprofessional&language=English&dictionary=Cancer.gov) (upper
[abdominal](/Common/PopUps/popDefinition.aspx?id=46684&version=healthprofessional&language=English&dictionary=Cancer.gov)) pain that required withdrawal of a small number of patients from
the study.[[5](#cit/section_6.5)] Other reported [side effects](/Common/PopUps/popDefinition.aspx?id=46580&version=healthprofessional&language=English&dictionary=Cancer.gov) have included dizziness,
[photophobia](/Common/PopUps/popDefinition.aspx?id=44077&version=healthprofessional&language=English&dictionary=Cancer.gov) (abnormal visual
sensitivity to light), irritability,[[5](#cit/section_6.5)] headache, heartburn, and
[fatigue](/Common/PopUps/popDefinition.aspx?id=321374&version=healthprofessional&language=English&dictionary=Cancer.gov).[[6](#cit/section_6.6)]

In a [prospective](/Common/PopUps/popDefinition.aspx?id=44079&version=healthprofessional&language=English&dictionary=Cancer.gov) study that explored the association between supplement use and [breast cancer](/Common/PopUps/popDefinition.aspx?id=444971&version=healthprofessional&language=English&dictionary=Cancer.gov) outcomes ([SWOG S0221](/clinicaltrials/NCT00070564)), the use of any [antioxidant](/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=English&dictionary=Cancer.gov) supplement before and during treatment–including coenzyme Q10, [vitamin A](/Common/PopUps/popDefinition.aspx?id=45248&version=healthprofessional&language=English&dictionary=Cancer.gov), [vitamin C](/Common/PopUps/popDefinition.aspx?id=439435&version=healthprofessional&language=English&dictionary=Cancer.gov), [vitamin E](/Common/PopUps/popDefinition.aspx?id=45023&version=healthprofessional&language=English&dictionary=Cancer.gov), and carotenoids–was associated with a trend showing an increased hazard of [recurrence](/Common/PopUps/popDefinition.aspx?id=45861&version=healthprofessional&language=English&dictionary=Cancer.gov) (adjusted hazard ratio, 1.41; confidence interval, 0.98–2.04, *P* = .06).[[7](#cit/section_6.7)]

Certain [lipid](/Common/PopUps/popDefinition.aspx?id=46068&version=healthprofessional&language=English&dictionary=Cancer.gov)-lowering drugs, such as the [statins](/Common/PopUps/popDefinition.aspx?id=390255&version=healthprofessional&language=English&dictionary=Cancer.gov) (lovastatin,
[pravastatin](/Common/PopUps/popDefinition.aspx?id=618548&version=healthprofessional&language=English&dictionary=Cancer.gov), and simvastatin) and gemfibrozil, as well as [oral](/Common/PopUps/popDefinition.aspx?id=44068&version=healthprofessional&language=English&dictionary=Cancer.gov) agents that
lower [blood](/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=English&dictionary=Cancer.gov) sugar, such as glyburide and tolazamide, cause a decrease in
[serum](/Common/PopUps/popDefinition.aspx?id=44088&version=healthprofessional&language=English&dictionary=Cancer.gov) levels of coenzyme Q10
and reduce the effects of coenzyme Q10 [supplementation](/Common/PopUps/popDefinition.aspx?id=45916&version=healthprofessional&language=English&dictionary=Cancer.gov).[[1](#cit/section_6.1),[8](#cit/section_6.8)-[10](#cit/section_6.10)] Beta-blockers (drugs that slow the heart rate and lower
[blood pressure](/Common/PopUps/popDefinition.aspx?id=462668&version=healthprofessional&language=English&dictionary=Cancer.gov)) can inhibit coenzyme Q10-dependent enzyme
reactions. The contractile force of the heart in patients with
[high blood pressure](/Common/PopUps/popDefinition.aspx?id=458091&version=healthprofessional&language=English&dictionary=Cancer.gov) can be increased by coenzyme Q10
administration.[[1](#cit/section_6.1)] Coenzyme Q10 can reduce the body’s
response to the [anticoagulant](/Common/PopUps/popDefinition.aspx?id=46082&version=healthprofessional&language=English&dictionary=Cancer.gov) drug
[warfarin](/Common/PopUps/popDefinition.aspx?id=45249&version=healthprofessional&language=English&dictionary=Cancer.gov).[[10](#cit/section_6.10)] Finally,
coenzyme Q10 can decrease [insulin](/Common/PopUps/popDefinition.aspx?id=46187&version=healthprofessional&language=English&dictionary=Cancer.gov) requirements in individuals with
[diabetes](/Common/PopUps/popDefinition.aspx?id=44911&version=healthprofessional&language=English&dictionary=Cancer.gov).

###### References

1. Pepping J: Coenzyme Q10. Am J Health Syst Pharm 56 (6): 519-21, 1999. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10192685&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10192685&dopt=Abstract")
2. Overvad K, Diamant B, Holm L, et al.: Coenzyme Q10 in health and disease. Eur J Clin Nutr 53 (10): 764-70, 1999. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10556981&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10556981&dopt=Abstract")
3. Hodges S, Hertz N, Lockwood K, et al.: CoQ10: could it have a role in cancer management? Biofactors 9 (2-4): 365-70, 1999. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10416054&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10416054&dopt=Abstract")
4. Heller JH: Disease, the host defense, and Q-10. Perspect Biol Med 16 (2): 181-7, 1973 Winter. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4689357&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4689357&dopt=Abstract")
5. Baggio E, Gandini R, Plancher AC, et al.: Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 15 (Suppl): s287-94, 1994. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752841&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752841&dopt=Abstract")
6. Feigin A, Kieburtz K, Como P, et al.: Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord 11 (3): 321-3, 1996. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8723151&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8723151&dopt=Abstract")
7. Ambrosone CB, Zirpoli GR, Hutson AD, et al.: Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol 38 (8): 804-814, 2020. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31855498&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31855498&dopt=Abstract")
8. Kaikkonen J, Nyyssönen K, Tuomainen TP, et al.: Determinants of plasma coenzyme Q10 in humans. FEBS Lett 443 (2): 163-6, 1999. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9989597&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9989597&dopt=Abstract")
9. Thibault A, Samid D, Tompkins AC, et al.: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2 (3): 483-91, 1996. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9816194&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9816194&dopt=Abstract")
10. Coenzyme Q10. In: Jellin JM, Hitchens K, eds.: Natural Medicines Comprehensive Database. Therapeutic Research Faculty, 1999, pp 241-42.

## Summary of the Evidence for Coenzyme Q10

To assist readers in evaluating the results of human [studies](/Common/PopUps/popDefinition.aspx?id=44195&version=healthprofessional&language=English&dictionary=Cancer.gov) of integrative, alternative, and complementary therapies for [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov), the strength of the evidence (i.e., the “[levels of
evidence](/Common/PopUps/popDefinition.aspx?id=446533&version=healthprofessional&language=English&dictionary=Cancer.gov)”) associated with each type of treatment is provided whenever
possible. To qualify for a level of evidence [analysis](/Common/PopUps/popDefinition.aspx?id=390238&version=healthprofessional&language=English&dictionary=Cancer.gov), a study must:

- Be published in a [peer-reviewed scientific journal](/Common/PopUps/popDefinition.aspx?id=537399&version=healthprofessional&language=English&dictionary=Cancer.gov).
- Report on a [therapeutic](/Common/PopUps/popDefinition.aspx?id=43985&version=healthprofessional&language=English&dictionary=Cancer.gov) [outcome](/Common/PopUps/popDefinition.aspx?id=467853&version=healthprofessional&language=English&dictionary=Cancer.gov) or outcomes, such as [tumor](/Common/PopUps/popDefinition.aspx?id=46634&version=healthprofessional&language=English&dictionary=Cancer.gov) [response](/Common/PopUps/popDefinition.aspx?id=44085&version=healthprofessional&language=English&dictionary=Cancer.gov), improvement in survival, or measured improvement in [quality of life](/Common/PopUps/popDefinition.aspx?id=45417&version=healthprofessional&language=English&dictionary=Cancer.gov).
- Describe clinical findings in sufficient detail that a meaningful evaluation can be made.

Separate levels of evidence scores are assigned to qualifying human studies on the basis of statistical strength of the study design and scientific strength of the treatment outcomes (i.e., [endpoints](/Common/PopUps/popDefinition.aspx?id=346519&version=healthprofessional&language=English&dictionary=Cancer.gov)) measured. The resulting two scores are then combined to produce an overall score. A table showing the levels of evidence scores for qualifying human studies cited in this summary is presented below. For an explanation of the scores and additional information about levels of evidence analysis for cancer, see [Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies](/publications/pdq/levels-evidence/cam).

Coenzyme Q10 Summary: Reference Numbers and the Corresponding Levels of Evidence

| Reference Number | Statistical Strength of Study Design | Strength of Endpoints Measured | Combined Score |
| --- | --- | --- | --- |
| [[1](#cit/section_7.1)] | 3iii ­ [Nonconsecutive case series](/Common/PopUps/popDefinition.aspx?id=44575&version=healthprofessional&language=English&dictionary=Cancer.gov) | Diii ­ Indirect surrogates -- tumor response rate | [3iiiDiii](/Common/PopUps/popDefinition.aspx?id=335158&version=HealthProfessional&language=English) |

###### References

1. Lockwood K, Moesgaard S, Hanioka T, et al.: Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 15 (Suppl): s231-40, 1994. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752835&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752835&dopt=Abstract")

## Latest Updates to This Summary (10/31/2024)

The [PDQ](/Common/PopUps/popDefinition.aspx?id=44271&version=healthprofessional&language=English&dictionary=Cancer.gov) [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov) information summaries are reviewed regularly and updated as
new information becomes available. This section describes the latest
changes made to this summary as of the date above.

Editorial changes were made to this summary.

This summary is written and maintained by the [PDQ Integrative, Alternative, and Complementary Therapies Editorial Board](https://www.cancer.gov/publications/pdq/editorial-boards/cam "https://www.cancer.gov/publications/pdq/editorial-boards/cam"), which is
editorially independent of NCI. The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH. More
information about summary policies and the role of the PDQ Editorial Boards in
maintaining the PDQ summaries can be found on the [About This PDQ Summary](/about-cancer/treatment/cam/hp/coenzyme-q10-pdq#_AboutThis_1) and [PDQ® Cancer Information for Health Professionals](https://www.cancer.gov/publications/pdq "https://www.cancer.gov/publications/pdq") pages.

## About This PDQ Summary

### Purpose of This Summary

This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of coenzyme Q10 in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.

### Reviewers and Updates

This summary is reviewed regularly and updated as necessary by the [PDQ Integrative, Alternative, and Complementary Therapies Editorial Board](https://www.cancer.gov/publications/pdq/editorial-boards/cam "https://www.cancer.gov/publications/pdq/editorial-boards/cam"), which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).

Board members review recently published articles each month to determine whether an article should:

- be discussed at a meeting,
- be cited with text, or
- replace or update an existing article that is already cited.

Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.

Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's [Email Us](https://www.cancer.gov/contact/email-us "https://www.cancer.gov/contact/email-us"). Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.

### Levels of Evidence

Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Integrative, Alternative, and Complementary Therapies Editorial Board uses a [formal evidence ranking system](/publications/pdq/levels-evidence/cam) in developing its level-of-evidence designations.

### Permission to Use This Summary

PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”

The preferred citation for this PDQ summary is:

PDQ® Integrative, Alternative, and Complementary Therapies Editorial Board. PDQ Coenzyme Q10. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: [https://www.cancer.gov/about-cancer/treatment/cam/hp/coenzyme-q10-pdq](https://www.cancer.gov/about-cancer/treatment/cam/hp/coenzyme-q10-pdq "https://www.cancer.gov/about-cancer/treatment/cam/hp/coenzyme-q10-pdq"). Accessed <MM/DD/YYYY>. [PMID: 26389329]

Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in [Visuals Online](https://visualsonline.cancer.gov/ "https://visualsonline.cancer.gov/"), a collection of over 2,000 scientific images.

### Disclaimer

The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the [Managing Cancer Care](https://www.cancer.gov/about-cancer/managing-care "https://www.cancer.gov/about-cancer/managing-care") page.

### Contact Us

More information about contacting us or receiving help with the Cancer.gov website can be found on our [Contact Us for Help](https://www.cancer.gov/contact "https://www.cancer.gov/contact") page. Questions can also be submitted to Cancer.gov through the website’s [Email Us](https://www.cancer.gov/contact/email-us "https://www.cancer.gov/contact/email-us").
